About

Mr. Penner has been a director of Celldex since the merger in March 2008 between Celldex and AVANT Immunotherapeutics and had been a director of AVANT since January 1997. In 2001, he founded Nascent BioScience, a firm engaged in the creation and development of new biotechnology companies, where he served as Chairman and Chief Executive Officer from 2001 to June 2023. From 1993 to 2001, Mr. Penner was President, Chief Executive Officer and Vice Chairman of Neurogen Corporation. From 1985 to 1993, he was an Executive Vice President of Novo Nordisk A/S, serving from 1988 to 1993 as Executive Vice President for North America and from 1985 to 1988 as the company’s Executive Vice President and General Counsel in Denmark. In addition to having served on the board of directors of several public and privately held life science companies, Mr. Penner is currently Chair of Wellcyte Innovations, Inc. He has served as BioScience Advisor to the Governor and the State of Connecticut, Chair of BioCT, Chair of the Connecticut Board of Governors of Higher Education and Chair of the Connecticut Technology Council. Mr. Penner received a B.A. from the University of Virginia, a J.D. from Fordham University and an L.L.M. in International Law from New York University.

Mr. Brownlie has been a director of Celldex since June 2017. He was employed by the accounting firm Ernst & Young LLP from 1974 to 2010, where he served as audit partner for numerous public companies and was the Life Sciences Industry Leader for the New York metropolitan area. He served as a member of the boards of directors and chair of the audit committees for multiple publicly-held biopharmaceutical companies including Soligenix, Inc., Phio Pharmaceuticals Corp. (formerly RXi Pharmaceuticals Corporation), EpiCept Corporation and Cancer Genetics, Inc. Mr. Brownlie received a B.S. in Accounting from Lehigh University and is a Certified Public Accountant.

Ms. Cohen has been a director of Celldex since June 2022. Ms. Cohen has served as President of CLC Consulting, a pharmaceutical and biotechnology consulting firm that specializes in new product start-ups and commercialization. From August 2011 to July 2014, Ms. Cohen served as Chief Commercial Officer of Medivation, Inc., where she built the company’s commercial organization and lead her team to successfully launch the oncology drug, Xtandi®. Prior to joining Medivation, Ms. Cohen spent over ten years at Johnson & Johnson, most notably as Vice President of the Rheumatology Franchise. Ms. Cohen began her career at Solvay Pharmaceuticals in management and sales. Ms. Cohen currently serves on the board of directors of Immunity Bio (previously NantKwest) and previously served on the board of directors of MEI Pharma and Ignyte Acquisition Corp., all of which are publicly traded companies. She earned a B. A. degree from Saint Joseph College.

Mr. Conrad has been a director of Celldex since March 2004. He was President of Roche Pharmaceuticals in the United States from 1982 until his retirement in 1993. Mr. Conrad serves as an advisor to the Seaver Autism Center at Mount Sinai Hospital. He previously served as Chairman of Pharmasset, GenVec and Bone Care International, and he served as a director of Matinas BioPharma Holdings, Arbutus Biopharmaceuticals and Reliant Pharmaceuticals, where he was a co-founder. Mr. Conrad received B.S. and M.S. degrees from the Brooklyn College of Pharmacy and an honorary doctorate in humane letters from Long Island University.

Dr. Jain has been a director of Celldex since February 2023. Dr. Jain is a rheumatologist. She previously served as Executive Vice President, Chief Medical Officer of ChemoCentryx, Inc., Chief Medical Officer of Immunovant, Inc. and prior to that, Senior Vice President and Chief Medical Officer of Akebia Therapeutics, Inc. Before joining Akebia, Dr. Jain served as Vice President of Men’s and Women’s Health and Metabolic Development at AbbVie, Inc. and in various leadership roles at Abbott Laboratories, including Divisional Vice President. Prior to her time at Abbott, she held management positions in the Arthritis, Inflammation and Pain Group at G.D. Searle, which was acquired by Pharmacia and, later, Pfizer. She was responsible for leading the design and execution of multiple late-stage programs, including for Orilissa^® and Oriahnn^® and has also led programs across a diverse set of therapeutic areas, including immunology, inflammation, pain and nephrology. Additionally, Dr. Jain served as Chief Executive Officer of Heartwood Biopharma Group, a private consulting group, and, earlier in her career, as a faculty member at North Shore University Hospital in New York. Dr. Jain currently serves as a member of the board of directors AnaptysBio, Inc. She previously served on the board of directors of Provention Bio, Inc., until its acquisition by Sanofi, ChemoCentryx, Inc., until its acquisition by Amgen, and on the supervisory board of AM Pharma. Dr. Jain received her M.D. from the State University of New York at Stony Brook School of Medicine and her B.S. in Biology from Long Island University.

Mr. Marino has been a director of Celldex since March 2017. Prior to July 2015, Mr. Marino was a Partner at the global law firm Dechert LLP for 28 years, where he served as Managing Partner of the Princeton, N.J. office and chair of the life science practice. His practice encompassed the representation of biotechnology companies in public and private financings, mergers and acquisitions, and strategic alliances. Previously he served as a member and as Chairman of the board of Traws Pharma, Inc., (formerly Onconova Therapeutics, Inc.), a publicly held biopharmaceutical company and as a member of the board of Pharmacopeia, Inc. He was a co-founder of BioNJ, a trade association of biotechnology companies based in New Jersey, and served as its counsel. Mr. Marino has worked in advisory capacities and on the boards of many non-profit organizations, including Robert Wood Johnson University Hospital, Wake Forest University Baptist Medical Center and Wake Forest University where he serves as a Life Trustee. Mr. Marino received his B.A., M.B.A. and his J.D. from Rutgers University.

Mr. Marucci was appointed President and Chief Executive Officer of Celldex in September 2008 and as a director of Celldex in December 2008. Since May 2003, Mr. Marucci has held a number of roles with Celldex, including as a founder, Vice President, Chief Financial Officer, Treasurer and Secretary. In addition, he was Treasurer of Medarex, Inc. (now a part of Bristol-Myers Squibb Co.) from December 1998 to March 2004. Mr. Marucci held a series of senior financial positions at Medarex from December 1998 to May 2003. Mr. Marucci is a member of the Board of Trustees of BioNJ Inc. and also served as its Treasurer through 2010. Mr. Marucci previously served as a member of the board of directors of Genenta Science S.p.A., a publicly held biopharmaceutical company and as a member of the Board of the College of Business and Public Management at Kean University. Mr. Marucci received his M.B.A. from Columbia University and his M.H.L. from Brown University.

Dr. Neil has been a director of Celldex since June 2022. Dr. Neil currently serves as Chief Executive Officer and Chair of the Board at Avalo Therapeutics, a publicly held biotechnology company. Prior to that, Dr. Neil was Senior Scientific Adviser and Chief Scientific Officer at Avalo since its February 2020 merger with Aevi Genomic Medicine, Inc., a biotechnology company where Dr. Neil had served as Chief Scientific Officer from September 2013 to February 2020. Prior to joining Aevi, Dr. Neil was a Partner at Apple Tree Partners, a life science private equity firm, from September 2012 to September 2013, and held a number of senior positions in the pharmaceutical industry, including most recently Corporate Vice President of Science & Technology at Johnson & Johnson from November 2007 to August 2012. Prior to these roles, Dr. Neil served as Group President at Johnson & Johnson Pharmaceutical Research and Development, Vice President of Research & Development at Merck KGaA/EMD Pharmaceuticals, and Vice President of Clinical Research at AstraZeneca and Astra Merck. Dr. Neil has served on the Board of Directors of Arena Pharmaceuticals, Inc. since February 2017 and as its Chair since February 2021. He previously served on the boards of Zura Bio Limited and GTx, Inc. both publicly traded biopharmaceutical companies. He is a member of the board of the Center for Discovery and Innovation of the Hackensack Meridian Medical School in Hackensack, New Jersey and is the Founding Chairman of TransCelerate Biopharma, Inc., a non-profit pharmaceuticals industry Research & Development consortium, and is a past member of the TransCelerate Board from 2012 to 2019. He served on the board of Reagan Udall Foundation for the FDA from 2007 – 2021, the board of Foundation for the National Institutes of Health (NIH) from 2010 – 2012 and on the Science Management Review board of the NIH from 2010 – 2012. Dr. Neil is also the past Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Executive Committee and the PhRMA Foundation board. Dr. Neil holds a B.S. from the University of Saskatchewan and an M.D. from the University of Saskatchewan College of Medicine. He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. Dr. Neil also completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic.

Ms. Torres has been a director of Celldex since June 2024. She currently serves as Chief Executive Officer of The Ignited Company, a Pennsylvania-based consulting firm she founded in 2017. From 2009 to 2017, she served in various senior leadership roles at Johnson & Johnson (J&J). From 2015 to 2017, she was Chief Strategy and Transformation Officer for J&J’s global medical device business, a $25 billion business with more than 50,000 employees. From 2011 to 2015, she was President of J&J McNeil Consumer Healthcare, where she led the recovery of OTC brands, including the iconic Tylenol portfolio, by transforming business operations, manufacturing, quality systems and commercialization approaches, and creating high levels of employee engagement across all functions of the business. From 2009 to 2011, she served as President of J&J Janssen Pharmaceuticals, Neuroscience, and from 2006-2009 she held various marketing positions at J&J. Ms. Torres was the sole recipient of the prestigious J&J HONOR award in 2016 for her work in diversity and inclusion, and she was named the 2015 Woman of the Year by the Healthcare Businesswomen’s Association. Before joining J&J, Ms. Torres built a successful, 14-year career at Eli Lilly and Company, where she focused on marketing and business unit management. Ms. Torres has served on the Board of Directors of publicly traded companies 2seventybio and Glaukos since 2021. She previously served on the boards of Karuna Therapeutics, Inc., Surface Oncology and Bluebird bio, Inc., all publicly traded biopharmaceutical companies. She is also the founder of The Mentoring Place, a nonprofit organization offering free executive mentoring to help women achieve their careers goals. Ms. Torres holds a B.S. in Psychology from Ball State University, a J.D. from Indiana University and an MBA from the University of Michigan. She is a member of the Michigan Bar Association.